Implementation and Interaction of Clinician And Patient-facing Tools Aiming to Intensify Neurohormonal Medicines for Heart Failure

Recruiting N/A Interventional Study
Heart Failure With Reduced Ejection Fraction
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Interventional
Purpose
Health Services Research
Participants needed
2,200 (estimated)
Sponsor
University of Colorado, Denver · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
An increasing number of guideline-directed medical therapies (GDMT) have been developed for patients with chronic heart failure with reduced ejection fraction (HFrEF). When used in combination at recommended doses, patients often experience significant improvements in cardiac function, quality of life, and survival.1,2 However, GDMT underuse occurs for the vast majority of patients with HFrEF. Two…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: Clinician: * Clinician (MD, PA, NP) who practices in cardiology outpatient clinics * Regularly sees patients with left ventricular ejection fraction (EF) \</=40%, where their panel of patients over the last year included at least 10 patients with heart failure with reduced ejec…
Contacts

Larry A Allen, MD, MHS

303-724-4713

larry.allen@cuanschutz.edu

CONTACT

Daniel D Matlock, MD, MPH

303-724-9941

daniel.matlock@cuanschutz.edu

CONTACT